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, the opiate analogue used, objective evidence of the programme's effectiveness will be a prerequisite to changing government service planning models.
Since addiction is a chronic condition and extended treatment has the best outcomes, the retention rate of participants in OST is often a key indicator of the effectiveness of such programmes. [10] We compared retention time and response to treatment (measured through duration until first use of heroin and number of positive tests during the treatment period) for heroin users receiving OST plus routine treatment and those receiving standard care only at SBRC during 2014.
Methods

Study design and population
This naturalistic retrospective study was approved by the Stellenbosch University Health Research Ethics Committee (ref. no. S15/02/031) and conducted according to locally and internationally accepted ethical guidelines. Records of all participants in the rehabilitation programme at SBRC from 1 January to 31 December 2014 were reviewed. All participants received the centre's standard care, which includes an intensive initial day programme based on the Matrix Model, [11] followed by an aftercare phase. The treatment (OST) group was additionally offered a fixed-dose combination of buprenorphine and naloxone (4:1) (the opiate analogue) in the 12-week clinician-monitored programme. The addition of naloxone is designed to prevent diversion and misuse of buprenorphine as it would precipitate opiate withdrawal if injected but not when ingested, because naloxone is poorly absorbed sublingually. Participants were accepted into the OST programme after detailed assessment by a multidisciplinary treatment team in accordance with local and international guidelines for psychosocially assisted pharmacological treatment of opioid dependence. The general goal of the investigation is to evaluate the participants' current and/or historical social, medical, psychological and legal profiles to aid in assessing motivation and treatment goals in order to formulate an effective treatment plan.
Data collection and analysis
Data were obtained from clinical case notes kept by the treating facility, which comprised an initial extensive clerking and records of positive urine tests and episodes of self-reported use. Prescriptions of the opiate analogue as well as dispensing information were recorded separately. Retention in the programme was measured from time of enrolment to the end of the programme or drop out. Also recorded were the number of urine samples provided, total number of positive tests or self-reported use events, and dates of first positive/ negative tests. General demographic data including sex, race, highest educational level attained and debut of substance abuse were also collected, as well as voluntary data on HIV status including date of last testing where available.
Data were summarised as means (standard deviations (SDs)) and medians (25th -75th percentiles or range) for continuous variables and as counts and percentages for categorical variables. Distribution of traits between the two treatment groups was assessed using tand χ 2 tests for quantitative and qualitative traits, respectively. All statistical analyses were performed using SPSS statistical software (version 23, IBM Corp., USA) and the level of statistical significance was set at p<0.05.
Results
Population demographics
The analysis excluded 33 records with missing core data and those from participants on a self-funded OST programme. Of the 135 analy sable records, 68 (50.4%) were from participants receiving standard care only and 67 (49.6%) from those also receiving OST ( Table 1 ). All participants were non-injecting users. The mean (SD) age was 28.5 (6.5) years, there were more males (91.1%) than females, and the majority were single (74.8%) and unemployed (96.3%). The 
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highest level of education attained was high school (grades 10 -12) for the majority (78.5%), and this was similar in both groups. An overwhelming majority of the participants (82.2%) had been arrested previously, and 17.1% admitted to current gang affiliation. Of the participants, 119 knew their HIV status, and 37.8% had been tested within the past year.
The mean debut age for use of illicit substances was 15.3 years (range 8 -36 years) and 74 participants (54.8%) reported current polydrug use, with the drugs most likely to be used together with heroin being methamphetamine (90.5%) and cannabis (39.2%) ( Table 2) .
Main outcomes
As shown in Table 3 , significantly more participants in the OST group (65.7%) than controls (44.1%) completed treatment (p=0.019). Among the non-completers, the retention rate was higher among OST participants than in the standard care group (48.2 v. 30.1 days; p=0.001). Participants in the OST group had a non-significant 2 days longer median duration to first positive drug test or self-reported use. The proportion of participants testing positive was higher in the OST group (80.6%) than in the standard care group (61.8%), although the former were tested nearly three times (18.3 v. 6.6 times) more. Consequently, the positive rate (proportion of positive tests) was substantially lower in the OST group (16.8%) than in the standard care group (23.3%). The dose of the opiate analogue prescribed in the OST group ranged from 2 mg to 16 mg (median 4 mg).
Discussion
The study evaluated the performance of SBRC, the first public-funded opioid substitution programme in SA, by comparing retention time and response to treatment with that of standard care. While the two programmes did not differ with regard to duration of abstinence from illicit opiate use during rehabilitation, we found that individuals in the OST group remained in treatment significantly longer and were more likely to complete the programme.
The proportion of participants completing treatment was significantly higher (65.7%) in the OST programme than in standard care (44.1%). Retention rates in treatment reported in the literature vary widely, but it is generally estimated that >50% of patients leave or are withdrawn in the first 3 weeks of treatment. [12] [13] [14] After 6 months of treatment, one study reported retention of 79%, [15] but others noted much lower rates of 58%, [16] 46% [17] and 27%. [18] In another study, an average of only 44% of buprenorphine clients spent at least 3 weeks in an Australian treatment facility. [19] The only other evaluation of an OST programme in Africa reported a retention rate of 57% over 2 years, [20] although it utilised methadone, which differs from buprenorphine with regard to retention. [17] The rate for the OST group in our study was therefore relatively high. Even among participants who did not complete treatment, those in the OST programme remained on average 18 days longer (p=0.001) than in the standard group. These findings concur with previous reports providing evidence of improved retention rates in OST-based rehabilitation programmes. [10] Response to treatment, denoted by a lower proportion of posi tive urine tests, was significantly higher in the OST group. However, abstinence from illicit opiates in this group was very low, as shown by the exceptionally high proportion of participants (80.6%) testing positive compared with other longer-term treatment programmes. [21] [22] While this may reflect international experience that longer periods than the SBRC's 12-week programme are necessary for higher abstinence, a possible reason for the low rate could be the high rate (54.8%) of concomitant use of other potentially destabilising drugs, which often leads to impulsive use of heroin during rehabilitation. [17] In addition, so that more participants could be included in a setting where funding was limited, a lower dose of the opiate analogue was used (median 4 mg) than that required to suppress illicit opioid use. While any dose above 2 mg retains participants in treatment, at least 16 mg is necessary to suppress illicit opioid use. [23] An encouraging finding was that the vast majority (88.1%) of the participants knew their HIV status, and more than a third had been tested within the past year. Similar positive findings were highlighted by South African Community Epidemiology Network on Drug Use (SACENDU) data [9] and may reflect successes made in community education pertaining to opioid use disorder as well as provision of access to confidential testing facilities. This is significant, as this population is at increased risk of contracting viral illness through high-risk behaviours such as unsafe sexual practices.
Study limitations
This study was limited by its retrospective nature, which precluded uniformity in terms of dosing, frequency of urine tests and client selection and restricted the range of variables assessed. The use of doses lower than those considered necessary to suppress illicit opioid use further limits the generalisability of the results. Future 
Conclusions
The results demonstrate a modest success of this pilot programme in terms of completion and retention rates and should argue for a move to increase availability of and accessibility to OSTs for management of opioid use disorder. This and future local programmes should consider extending treatment duration, as longer treatment is often required for long-term recovery from opioid addiction. [24] Future studies should evaluate performance of these extended programmes, and include the wider and more robust outcomes mentioned earlier, together with additional measures such as more intensive psychosocial support with possible penalties for early dropouts.
The design of such studies should also allow for a more systematic collection of data where variables, such as frequency of urine tests, are uniform and consistent to allow better analysis, interpretation and utility for evidence-based quality improvement. More investments in financial and human resources will be needed to address comorbid drug use, gang affiliation and skilling participants to enhance prospects for gainful occupation. To improve retention, consideration can also be given to inclusion of employment assistance, as some authors have suggested. [25] 
